When Pfizer patented its new discovery of second medical use of sildenafil globally for Viagra, it met extensive challenges in many countries, with reasons of, among others, obviousness and insufficient disclosure. As ruled by the courts or patent offices in several countries, patent claims should not go beyond what the inventor disclosed to the public, or it may violate the basic rationale of ...